Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study

被引:43
|
作者
Varisco, Valentina [1 ]
Vigano, Mauro [2 ]
Batticciotto, Alberto [1 ]
Lampertico, Pietro
Marchesoni, Antonio [3 ]
Gibertini, Patrizia [3 ]
Pellerito, Raffaele [4 ]
Rovera, Guido [4 ]
Caporali, Roberto [5 ]
Todoerti, Monica [5 ]
Covelli, Michele
Notarnicola, Antonella [6 ]
Atzeni, Fabiola [1 ]
Sarzi-Puttini, Piercarlo [1 ]
机构
[1] Osped L Sacco, Rheumatol Unit, Via GB Grassi 74, I-20157 Milan, Italy
[2] Univ Milan, Osped San Giuseppe, Hepatol Unit, Milan, Italy
[3] Ist Ortoped G Pini, Rheumatol Day Hosp, Milan, Italy
[4] Osped Mauriziano Umberto 1, Rheumatol Unit, Turin, Italy
[5] Univ Pavia, IRCCS Fdn San Matteo, Div Rheumatol, Pavia, Italy
[6] Azienda Osped Univ AOU Policlin, Univ Rheumatol Dept, Bari, Italy
关键词
HEPATITIS B VIRUS REACTIVATION; HBsAg; HBV DNA; RITUXIMAB; RHEUMATOID ARTHRITIS; CELL LYMPHOMA PATIENTS; CHEMOTHERAPY; INFECTION; MANAGEMENT; DISEASE; EPIDEMIOLOGY; PROPHYLAXIS; COMBINATION; ANTIBODY; PATIENT;
D O I
10.3899/jrheum.151105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Patients with resolved hepatitis B virus (HBV) infection, i.e., hepatitis B surface antigen (HBsAg)-negative/antihepatitis B core antigen (anti-HBc)-positive, undergoing rituximab (RTX)-based chemotherapy for hematological malignancies without anti-HBV prophylaxis are at risk of HBV reactivation, but the risk in such patients receiving RTX for rheumatological disorders is not clear. We evaluated this risk in HBsAg-negative/anti-HBc positive patients with rheumatoid arthritis (RA) undergoing RTX without prophylaxis. Methods. Thirty-three HBsAg-negative/ anti-HBc-positive outpatients with RA with undetectable HBV DNA by sensitive PCR assay [73% women, median age 60 years, 85% with HBsAg antibodies (anti-HBs), 37% with antihepatitis B envelope antigen] received a median of 3 cycles of RTX (range 1-8) over 34 months (range 0-80) combined with disease-modifying antirheumatic drugs (DMARD) without prophylaxis. All underwent clinical and laboratory monitoring during and after RTX administration, including serum HBsAg and HBV DNA measurements every 6 months or whenever clinically indicated. Results. None of the patients seroreverted to HBsAg during RTX treatment, but 6/28 (21%) showed a > 50% decrease in protective anti-HBs levels, including 2 who became anti-HBs-negative. One patient (3%) who became HBV DNA-positive (44 IU/ml) after 6 months of RTX treatment was effectively rescued with lamivudine before any hepatitis flare occurred. Among the 14 patients monitored for 18 months (range 0-70) after RTX discontinuation, no HBV reactivation was observed. Conclusion. The administration of RTX + DMARD in patients with RA with resolved HBV infection leads to a negligible risk of HBV reactivation, thus suggesting that serum HBsAg and/or HBV DNA monitoring but not universal anti-HBV prophylaxis is justified.
引用
收藏
页码:869 / 874
页数:6
相关论文
共 50 条
  • [1] HEPATITIS B VIRUS REACTIVATION IN RHEUMATOID ARTHRITIS PATIENTS WITH HBSAG-NEGATIVE/ANTI-HBC-POSITIVE STATUS
    Ho, C. -H.
    Leung, M. H. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1342 - 1342
  • [2] LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBSAG NEGATIVE, ANTI-HBC POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITIS
    Vigano, M.
    Varisco, V.
    Lampertico, P.
    Batticciotto, A.
    Marchesoni, A.
    Gibertini, P.
    Pellerito, R.
    Rovera, G.
    Caporali, R.
    Todoerti, M.
    Covelli, M.
    Notarnicola, A.
    Colombo, M.
    Sarzi-Puttini, P.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E23 - E23
  • [3] LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBsAg NEGATIVE, ANTI-HBc POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITIS
    Vigano, M.
    Varisco, V.
    Lampertico, P.
    Batticciotto, A.
    Mascheroni, A.
    Gibertini, P.
    Pellerito, R.
    Rovera, G.
    Caporali, R.
    Todoerti, M.
    Covelli, M.
    Notarnicola, A.
    Colombo, M.
    Sarzi-Puttini, P.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S287 - S288
  • [4] Rituximab and hepatitis B reactivation in HBsAg-negative/anti-HBc-positive kidney transplant recipients
    Lee, Juhan
    Park, Jun Yong
    Huh, Kyu Ha
    Kim, Beom Seok
    Kim, Myoung Soo
    Kim, Soon Il
    Ahn, Sang Hoon
    Kim, Yu Seun
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (04) : 722 - 729
  • [5] The Risk of Hepatitis B Virus Reactivation in HBsAg-Negative and Anti-HBc-Positive Patients Receiving Tumor Necrosis Factor Antagonists
    Pauley, Mary Patricia
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (01) : 210 - 211
  • [6] Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review
    Cholongitas, Evangelos
    Haidich, Anna-Bettina
    Apostolidou-Kiouti, Fani
    Chalevas, Parthenis
    Papatheodoridis, George V.
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (04): : 480 - 490
  • [7] HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?
    Linda Drößler
    Clara Lehmann
    Karin Töpelt
    Dirk Nierhoff
    Jörg J. Vehreschild
    Jan Rybniker
    Michael Hallek
    Julia Fischer
    Verena Stormberg
    Gerd Fätkenheuer
    Ulrike Wieland
    Norma Jung
    Infection, 2019, 47 : 293 - 300
  • [8] HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?
    Droessler, Linda
    Lehmann, Clara
    Toepelt, Karin
    Nierhoff, Dirk
    Vehreschild, Joerg J.
    Rybniker, Jan
    Hallek, Michael
    Fischer, Julia
    Stormberg, Verena
    Faetkenheuer, Gerd
    Wieland, Ulrike
    Jung, Norma
    INFECTION, 2019, 47 (02) : 293 - 300
  • [9] Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib
    Garcia-Horton, Alejandro
    Smith, Elliot
    Maze, Dawn
    McNamara, Caroline
    Sibai, Hassan
    Gupta, Vikas
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 495 - 497
  • [10] The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients.
    Lee, J.
    Park, J.
    Jung, Y.
    Kim, D.
    Lee, J.
    Song, S.
    Lee, J.
    Lee, J.
    Kim, B.
    Kim, M.
    Kim, S.
    Kim, Y.
    Huh, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 263 - 263